Skip to main content
All lobbying filings

Williams and Jensen, PLLC

Williams and Jensen, PLLC filed a Q3 report for Beone Medicines ( Formerly Known as Beigene USA, Inc.) on October 20, 2025, reporting $80,000 in lobbying income.

Lobbying for Beone Medicines ( Formerly Known as Beigene USA, Inc.) · Healthcare/Pharmaceuticals

As filed: WILLIAMS AND JENSEN, PLLC for BEONE MEDICINES ( FORMERLY KNOWN AS BEIGENE USA, INC.).

All filings by Williams and Jensen, PLLC · Everything Beone Medicines ( Formerly Known as Beigene USA, Inc.) has reported

 Amended
The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Oct 20, 2025.
 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$80,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 1
  • JEANNE HAGGERTY New on this filing
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Health Issues

Monitor progress of next Prescription Drug User Fee Reauthorization, issues relating to US and international manufacturing, oncology issues, FDA reorganization and programs, 340B, monitoring efforts around direct-to-consumer policies.

Trade (domestic/foreign)

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing), access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

Manufacturing

Monitoring efforts to onshore and build US pharmaceutical manufacturing capacity.

Pharmacy

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

 Bills named in this filing 2

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem